SMS Pharmaceuticals · NSE: SMSPHARMA · BSE: 532815
Q3 FY21 results · Oct–Dec 2020
SMS Pharmaceuticals reported revenue from operations of ₹148.87 crore (up 85.0% from Q3 FY20) and net profit of ₹21.39 crore (up 185.2% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 148.87 | 80.45 | +85.0% | 130.13 | +14.4% |
| Other income | 0.86 | 0.79 | +8.0% | 0.92 | −6.5% |
| Total income | 149.72 | 81.24 | +84.3% | 131.04 | +14.3% |
| Profit before tax | 26.75 | 12.50 | +114.0% | 16.25 | +64.5% |
| Net profit for the period | 21.39 | 7.50 | +185.2% | 11.23 | +90.6% |
| EPS, basic (₹) | 2.53 | 0.90 | +181.1% | 1.33 | +90.2% |
| Net margin (%) | 14.4 | 9.3 | 8.6 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 148.87 | 80.45 | +85.0% | 130.13 | +14.4% |
| Other income | 0.86 | 0.79 | +8.0% | 0.92 | −6.5% |
| Total income | 149.72 | 81.24 | +84.3% | 131.04 | +14.3% |
| Profit before tax | 26.75 | 12.50 | +114.0% | 16.25 | +64.5% |
| Net profit for the period | 18.32 | 7.50 | +144.3% | 11.23 | +63.2% |
| EPS, basic (₹) | 2.16 | 0.89 | +142.7% | 1.33 | +62.4% |
| Net margin (%) | 12.3 | 9.3 | 8.6 |
Consolidated
- Filed with BSE
- 11 Feb 2021, 12:41 IST
- Board meeting
- 10 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Feb 2021, 12:41 IST
- Board meeting
- 10 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE